EP Patent

EP1114644A1 — Composition comprising NPH insulin (neutral protamine hagedorn insulin)

Assigned to Genentech Inc · Expires 2001-07-11 · 25y expired

What this patent protects

Formulations containing NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation comprises NPH insulin in an acetic acid salt buffer.

USPTO Abstract

Formulations containing NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation comprises NPH insulin in an acetic acid salt buffer.

Drugs covered by this patent

Patent Metadata

Patent number
EP1114644A1
Jurisdiction
EP
Classification
—
Expires
2001-07-11
Drug substance claim
No
Drug product claim
No
Assignee
Genentech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.